Beikabuzukan
日本語
Watchlist

Alector, Inc.

Overview

Financials

Units: $M (per-share in $, ratios in %)

Revenue & profit

Margins

Valuation

Multiples at each fiscal year end (annual) and current (TTM)

Valuation history

Segments

Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.

By product

By region

Dividends & earnings

Annual dividend per share ($, split-adjusted)

EPS (diluted), last 16 quarters ($)

Company info

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.